Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BGBA1217 + Carboplatin + Etoposide + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BGBA1217||BGB-A1217|BGB A1217|Ociperlimab||TIGIT Antibody 13||BGBA1217 is a monoclonal antibody that binds to TIGIT and blocks its interaction with Nectin-2 (CD112) and Nectin-like protein 5 (CD155), which results in increased interaction of CD112 and CD155 with the co-stimulatory receptor CD226 and activation of downstream signaling, potentially inducing immune response against tumor cells (NCI Thesaurus).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04047862||Phase I||BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab||Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors||Recruiting||USA||5|